181 related articles for article (PubMed ID: 27821484)
1. PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis.
Zhou X; Updegraff BL; Guo Y; Peyton M; Girard L; Larsen JE; Xie XJ; Zhou Y; Hwang TH; Xie Y; Rodriguez-Canales J; Villalobos P; Behrens C; Wistuba II; Minna JD; O'Donnell KA
Cancer Res; 2017 Jan; 77(1):187-197. PubMed ID: 27821484
[TBL] [Abstract][Full Text] [Related]
2. Modulation of Mutant
Zhou X; Padanad MS; Evers BM; Smith B; Novaresi N; Suresh S; Richardson JA; Stein E; Zhu J; Hammer RE; O'Donnell KA
Mol Cancer Res; 2019 Feb; 17(2):594-603. PubMed ID: 30409919
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
[TBL] [Abstract][Full Text] [Related]
4. Protocadherin 7 is overexpressed in castration resistant prostate cancer and promotes aberrant MEK and AKT signaling.
Shishodia G; Koul S; Koul HK
Prostate; 2019 Nov; 79(15):1739-1751. PubMed ID: 31449679
[TBL] [Abstract][Full Text] [Related]
5. ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer.
Baumgart A; Seidl S; Vlachou P; Michel L; Mitova N; Schatz N; Specht K; Koch I; Schuster T; Grundler R; Kremer M; Fend F; Siveke JT; Peschel C; Duyster J; Dechow T
Cancer Res; 2010 Jul; 70(13):5368-78. PubMed ID: 20551051
[TBL] [Abstract][Full Text] [Related]
6. Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo.
Elsum IA; Yates LL; Pearson HB; Phesse TJ; Long F; O'Donoghue R; Ernst M; Cullinane C; Humbert PO
Oncogene; 2014 Nov; 33(48):5523-33. PubMed ID: 24276238
[TBL] [Abstract][Full Text] [Related]
7. KRAS
Zhou ZW; Ambrogio C; Bera AK; Li Q; Li XX; Li L; Son J; Gondi S; Li J; Campbell E; Jin H; Okoro JJ; Xu CX; Janne PA; Westover KD
Cancer Res; 2020 Sep; 80(17):3719-3731. PubMed ID: 32605999
[TBL] [Abstract][Full Text] [Related]
8. JMJD1A promotes tumorigenesis and forms a feedback loop with EZH2/let-7c in NSCLC cells.
Zhan M; Wen F; Liu L; Chen Z; Wei H; Zhou H
Tumour Biol; 2016 Aug; 37(8):11237-47. PubMed ID: 26945572
[TBL] [Abstract][Full Text] [Related]
9. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.
Chou YT; Lin HH; Lien YC; Wang YH; Hong CF; Kao YR; Lin SC; Chang YC; Lin SY; Chen SJ; Chen HC; Yeh SD; Wu CW
Cancer Res; 2010 Nov; 70(21):8822-31. PubMed ID: 20978205
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer.
Yang L; Amann JM; Kikuchi T; Porta R; Guix M; Gonzalez A; Park KH; Billheimer D; Arteaga CL; Tai HH; DuBois R; Carbone DP; Johnson DH
Cancer Res; 2007 Jun; 67(12):5587-93. PubMed ID: 17575121
[TBL] [Abstract][Full Text] [Related]
11. SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A.
Hung MH; Wang CY; Chen YL; Chu PY; Hsiao YJ; Tai WT; Chao TT; Yu HC; Shiau CW; Chen KF
Oncotarget; 2016 Jan; 7(1):638-55. PubMed ID: 26575017
[TBL] [Abstract][Full Text] [Related]
12. Derlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9.
Dong QZ; Wang Y; Tang ZP; Fu L; Li QC; Wang ED; Wang EH
Am J Pathol; 2013 Mar; 182(3):954-64. PubMed ID: 23306155
[TBL] [Abstract][Full Text] [Related]
13. Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.
Kim JY; Welsh EA; Fang B; Bai Y; Kinose F; Eschrich SA; Koomen JM; Haura EB
Mol Cancer Res; 2016 Oct; 14(10):1019-1029. PubMed ID: 27422710
[TBL] [Abstract][Full Text] [Related]
14. Parthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/MAPK/Erk pathway.
Lin M; Bi H; Yan Y; Huang W; Zhang G; Zhang G; Tang S; Liu Y; Zhang L; Ma J; Zhang J
Oncotarget; 2017 Apr; 8(14):23436-23447. PubMed ID: 28423582
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
Green S; Trejo CL; McMahon M
Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer.
Lee HY; Chun KH; Liu B; Wiehle SA; Cristiano RJ; Hong WK; Cohen P; Kurie JM
Cancer Res; 2002 Jun; 62(12):3530-7. PubMed ID: 12068000
[TBL] [Abstract][Full Text] [Related]
17. CMTM7 knockdown increases tumorigenicity of human non-small cell lung cancer cells and EGFR-AKT signaling by reducing Rab5 activation.
Liu B; Su Y; Li T; Yuan W; Mo X; Li H; He Q; Ma D; Han W
Oncotarget; 2015 Dec; 6(38):41092-107. PubMed ID: 26528697
[TBL] [Abstract][Full Text] [Related]
18. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
19. Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression.
Cicchini M; Buza EL; Sagal KM; Gudiel AA; Durham AC; Feldser DM
Cell Rep; 2017 Feb; 18(8):1958-1969. PubMed ID: 28228261
[TBL] [Abstract][Full Text] [Related]
20. Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.
Matsubara D; Ishikawa S; Oguni S; Aburatani H; Fukayama M; Niki T
J Thorac Oncol; 2010 Sep; 5(9):1317-24. PubMed ID: 20736805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
